-
Product Insights
NewDecompensated Cirrhosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Decompensated Cirrhosis Clinical Trial Report Overview A total of 227 Decompensated Cirrhosis clinical trials were conducted as of April 2024. The Decompensated Cirrhosis Clinical Trial report provides an overview of the Decompensated Cirrhosis Clinical Trial scenario. This report provides top-line data relating to the clinical trials on Decompensated Cirrhosis. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
NewEpilepsy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Epilepsy Clinical Trial Report Overview A total of 3474 epilepsy clinical trials were conducted as of April 2024. The epilepsy clinical trial report provides a comprehensive understanding of the epilepsy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · North America · Europe · Asia-Pacific · ...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Sector Analysis
NewMethicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
Methicillin-Resistant Staphylococcus aureus (MRSA) Report Overview In the 7MM, there were 714,131 hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) in 2023. The hospitalized incident cases of Methicillin-Resistant Staphylococcus aureus (MRSA) will register an AGR of more than 1% during 2023-2033. Methicillin-resistant Staphylococcus aureus (MRSA) is a virulent, antibiotic-resistant bacteria that is associated with considerable morbidity and mortality. MRSA can be categorized according to the setting in which the infection was acquired, as either healthcare-associated MRSA (HA-MRSA), which is acquired...
-
Thematic Analysis
Psychedelics Therapeutics Development and Trends, 2024
This report provides a summary of the current and future state of the psychedelic therapeutic sector, offering a high-level analysis of key trends and developments within the industry, including regulatory, clinical, and market dynamics. The report identifies the broader changes within the evolving psychedelic industry, facilitating informed decision-making for relevant sectors.
-
Sector Analysis
Resistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Resistant Hypertension (RH) Marketed and Pipeline Drugs Report Overview Resistant Hypertension (RH) refers to high blood pressure (BP) that is above the target level in a patient. This occurs even when they are taking three different classes of antihypertensive medications concurrently. These medication classes typically include diuretics, long-acting calcium channel blockers, and renin-angiotensin system blockers (ACEs or ARBs). The Resistant Hypertension (RH) marketed, and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales...
-
Sector Analysis
Retinitis Pigmentosa (RP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Retinitis Pigmentosa (RP) Marketed and Pipeline Drugs Report Overview Retinitis pigmentosa (RP) is a cluster of rare eye conditions. One of these conditions causes degeneration of the retina, the light-sensitive layer at the back of the eye. This degeneration results in a progressive loss of vision. Retinitis pigmentosa is an inherited genetic disorder. Most people have progressive vision loss over time, with symptoms usually starting in childhood. While there isn't a cure at this time, people can maximize their residual...
-
Sector Analysis
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges
Antibody-Drug Conjugates Market Report Overview An Antibody-Drug Conjugates (ADC) drug consists of monoclonal antibodies conjugated to a payload via a linker, for the precise targeting of antigen-positive cancer cells. ADCs are developed to target protein receptors with high expression such as HER2, TROP-2, CD22, and others. There are two cytotoxic payload types predominantly used in ADCs including microtubule inhibitors, and the more potent DNA-damaging payloads such as topoisomerase I inhibitors. The ADC market research report will aid clients in gaining...
-
Sector Analysis
Peripheral Artery Disease (PAD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Peripheral Artery Disease Marketed and Pipeline Drugs Report Overview PAD is an atherosclerotic disease in which the formation of atherosclerotic plaque causes narrowing of the arteries and poor perfusion to the limbs. This can progress to arterial occlusion and chronic limb-threatening ischemia (CLTI). PAD can happen in any blood vessel, but it is more common in the legs than the arms. Key Mechanisms of Action (Marketed) · Receptor Agonist · Enzyme Inhibitor · Biological Factor Activator · Ligand Inhibitor · ...